Safety and Health at Work Vol. 12 Issue 2 2021
Risk Assessment for Toluene Diisocyanate and Respiratory Disease Human Studies (Original article)
Dublin Core
Title
Safety and Health at Work Vol. 12 Issue 2 2021
Risk Assessment for Toluene Diisocyanate and Respiratory Disease Human Studies (Original article)
Risk Assessment for Toluene Diisocyanate and Respiratory Disease Human Studies (Original article)
Subject
Asthma, Lung cancer, Pulmonary function, Survivor bias, Toluene diisocyanate
Description
Background: Toluene diisocyanate (TDI) is a highly reactive chemical that causes sensitization and has
also been associated with increased lung cancer. A risk assessment was conducted based on occupational epidemiologic estimates for several health outcomes.
Methods: Exposure and outcome details were extracted from published studies and a NIOSH Health Hazard Evaluation for new onset asthma, pulmonary function measurements, symptom prevalence, and mortality from lung cancer and respiratory disease. Summary exposureeresponse estimates were calculated taking into account relative precision and possible survivor selection effects. Attributable incidence of sensitization was estimated as were annual proportional losses of pulmonary function. Excess lifetime risks and benchmark doses were calculated.
Results: Respiratory outcomes exhibited strong survivor bias. Asthma/sensitization exposure response decreased with increasing facility-average TDI air concentration as did TDI-associated pulmonary impairment. In a mortality cohort where mean employment duration was less than 1 year, survivor bias pre-empted estimation of lung cancer and respiratory disease exposure response.
Conclusion: Controlling for survivor bias and assuming a linear doseeresponse with facility-average TDI concentrations, excess lifetime risks exceeding one per thousand occurred at about 2 ppt TDI for sensitization and respiratory impairment. Under alternate assumptions regarding stationary and cumulative effects, one per thousand excess risks were estimated at TDI concentrations of 10 e 30 ppt. The unexplained reported excess mortality from lung cancer and other lung diseases, if attributable to TDI or associated emissions, could represent a lifetime risk comparable to that of sensitization.
also been associated with increased lung cancer. A risk assessment was conducted based on occupational epidemiologic estimates for several health outcomes.
Methods: Exposure and outcome details were extracted from published studies and a NIOSH Health Hazard Evaluation for new onset asthma, pulmonary function measurements, symptom prevalence, and mortality from lung cancer and respiratory disease. Summary exposureeresponse estimates were calculated taking into account relative precision and possible survivor selection effects. Attributable incidence of sensitization was estimated as were annual proportional losses of pulmonary function. Excess lifetime risks and benchmark doses were calculated.
Results: Respiratory outcomes exhibited strong survivor bias. Asthma/sensitization exposure response decreased with increasing facility-average TDI air concentration as did TDI-associated pulmonary impairment. In a mortality cohort where mean employment duration was less than 1 year, survivor bias pre-empted estimation of lung cancer and respiratory disease exposure response.
Conclusion: Controlling for survivor bias and assuming a linear doseeresponse with facility-average TDI concentrations, excess lifetime risks exceeding one per thousand occurred at about 2 ppt TDI for sensitization and respiratory impairment. Under alternate assumptions regarding stationary and cumulative effects, one per thousand excess risks were estimated at TDI concentrations of 10 e 30 ppt. The unexplained reported excess mortality from lung cancer and other lung diseases, if attributable to TDI or associated emissions, could represent a lifetime risk comparable to that of sensitization.
Creator
Robert M. PARK
Publisher
Elsevier Korea LLC
Date
June 2021
Contributor
Sri Wahyuni
Format
PDF
Language
English
Type
Text
Coverage
Safety and Health at Work Vol. 12 Issue 2 2021
Files
Citation
Robert M. PARK, “Safety and Health at Work Vol. 12 Issue 2 2021
Risk Assessment for Toluene Diisocyanate and Respiratory Disease Human Studies (Original article),” Repository Horizon University Indonesia, accessed April 4, 2025, https://repository.horizon.ac.id/items/show/2160.
Risk Assessment for Toluene Diisocyanate and Respiratory Disease Human Studies (Original article),” Repository Horizon University Indonesia, accessed April 4, 2025, https://repository.horizon.ac.id/items/show/2160.